CXCL13 and neoplasm: Notably, HER2-CXCR5-CCR6-CAR T cells demonstrated significantly enhanced tumor infiltration compared to conventional HER2-CAR T cells, attributable to their triple-targeting capacity for tumor sites co-expressing HER2, CXCL13, and CCL20.